Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1426 studies found for:    Kennedy's Disease
Show Display Options
RSS Create an RSS feed from your search for:
Kennedy's Disease
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting MRI in Patients With Kennedy Disease
Conditions: Bulbo-Spinal Atrophy, X-Linked;   Kennedy Disease
Intervention: Other: No intervention, observational
2 Completed
Has Results
Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)
Conditions: Kennedy's Disease;   Spinal and Bulbar Muscular Atrophy
Interventions: Drug: Dutasteride;   Drug: Placebo
3 Completed Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy
Conditions: Spinobulbar Muscular Atrophy;   Kennedy's Disease
Interventions: Drug: Goserelin;   Procedure: Electrophysiologic study;   Procedure: tissue biopsy
4 Unknown  High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy
Conditions: Spinal and Bulbar Muscular Atrophy;   Healthy Subjects
Interventions: Other: Supervised high intensity training;   Other: Optional training;   Other: Control period;   Other: Unsupervised High intensity training
5 Active, not recruiting Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Condition: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Intervention: Drug: Enzalutamide
6 Completed Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors
Condition: Advanced Solid Tumours With Androgen Receptor Pathway as a Potential Factor
Intervention: Drug: AZD5312
7 Not yet recruiting A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: LY2452473;   Drug: Placebo
8 Completed Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia
Condition: Androgenetic Alopecia
Intervention: Drug: Finasteride
9 Completed Phase II Study of Leuprolide and Testosterone for Men With Kennedy's Disease or Other Motor Neuron Disease
Conditions: Spinal Muscular Atrophy;   Amyotrophic Lateral Sclerosis;   Spinobulbar Muscular Atrophy
Interventions: Drug: leuprolide;   Drug: testosterone
10 Completed Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy
Condition: Spinal and Bulbar Muscular Atrophy
Interventions: Drug: BVS857;   Drug: Placebo
11 Recruiting Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Conditions: Advanced Epithelial Ovarian;   Recurrent Epithelial Ovarian;   Fallopian Tube;   Primary Peritoneal Carcinoma
Intervention: Drug: Enzalutamide
12 Terminated A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)
Conditions: Metastatic Breastcancer;   Estrogen Receptor Positive Breast Cancer;   Estrogen Receptor Negative Neoplasm;   Progesterone Receptor Positive Tumor;   Progesterone Receptor Negative Neoplasm;   Androgen Receptor Gene Overexpression
Intervention: Drug: DHEA
13 Completed Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women
Conditions: Libido;   Receptors, Androgen;   Polymorphism, Genetic;   Androgen Effect
Intervention:
14 Not yet recruiting Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Conditions: Androgen Receptor Positive;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Enobosarm;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
15 Recruiting Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Adenocarcinoma
Interventions: Drug: Enzalutamide;   Other: Laboratory Biomarker Analysis;   Drug: Niclosamide;   Other: Pharmacological Study
16 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
17 Not yet recruiting Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Conditions: Stage II Prostate Adenocarcinoma;   Stage III Prostate Adenocarcinoma
Interventions: Drug: Abiraterone Acetate;   Drug: Androgen Receptor Antagonist ARN-509;   Biological: Gonadotropin-releasing Hormone Analog;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Radical Prostatectomy
18 Recruiting Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: Biomarker Analysis;   Drug: Enzalutamide;   Other: Pharmacological Study;   Drug: Taselisib
19 Recruiting Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling
Condition: Prostate Cancer
Intervention: Drug: Enzalutamide
20 Recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.